Q2 2024 Genomma Lab Internacional SAB de CV Earnings Call Transcript
Key Points
- Genomma Lab Internacional SAB de CV (GNMLF) reported a strong gross margin of 64%, marking a 7.1-point improvement over the past 1.5 years.
- EBITDA margin increased to 22.9%, a 186 basis points rise compared to the previous year.
- Net income grew by 50.1% to MXN631 million, with EPS increasing by 53.1% to MXN0.63.
- The company completed strategic M&As, including acquisitions in the US and Argentina, expected to enhance growth in core brands.
- Genomma Lab Internacional SAB de CV (GNMLF) achieved 41% of its MXN1,800 million productivity savings target as of Q2 2024.
- The cash conversion cycle extended to 122 days, influenced by hyperinflationary accounting in Argentina and reduced supplier days.
- Challenges were noted in the Skincare category, with Asepxia and Cicatricure brands facing mixed performance.
- Macroeconomic headwinds, including the strengthening of the Mexican peso, impacted results in some regions.
- Sales in Chile and Peru faced headwinds, with Chile experiencing a consumption contraction and Peru affected by government policy changes.
- The company is still navigating a highly volatile macro environment, impacting figures in countries like Chile and Brazil.
Greetings, ladies and gentlemen. Thank you for joining Genomma's Lab's second quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this meeting is being recorded and will be available for replay from the Investor Relations section of Genomma's website, following the call.
I'll now turn the call over to Christianne Ibanez, Genomma's Head of Investor Relations. Please go ahead.
Thank you, and welcome, everyone. On today's call are Marco Sparvieri, Chief Executive Officer; and Antonio Zamora, Chief Financial Officer.
Before we get started, I'd like to remind you that the remarks today will include forward-looking statements, such as the company's financial guidance and expectations, including long-term objectives and forecasts as well as expectations regarding to Genomma's business, assets, products, strategies, demand and markets. These statements are subject to risks and uncertainties that could cause actual results to differ
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
